Gilead Sciences, Inc.
CH ˙ SWX ˙ US3755581036
SecurityCH:GILD / Gilead Sciences, Inc.
InstitutionBelpointe Asset Management LLC
Latest Disclosed Ownership6,712 shares
Latest Disclosed Value $ 935,483
Belpointe Asset Management LLC reports 9.85% increase in ownership of GILD / Gilead Sciences, Inc.

On April 28, 2026 - Belpointe Asset Management LLC filed a 13F-HR form disclosing ownership of 6,712 shares of Gilead Sciences, Inc. (CH:GILD) valued at $935,483 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 27, 2026 disclosing 6,110 shares of Gilead Sciences, Inc.. This represents a change in shares of 9.85% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-28 2026-03-31 13F GILEAD SCIENCES COM 375558103 6,712 602 9.85 935 24.67 0.0341
2026-01-27 2025-12-31 13F GILEAD SCIENCES COM 375558103 6,110 439 7.74 750 19.24 0.0271
2025-11-03 2025-09-30 13F GILEAD SCIENCES COM 375558103 5,671 124 2.24 629 2.28 0.0240
2025-07-22 2025-06-30 13F GILEAD SCIENCES COM 375558103 5,547 -1,880 -25.31 615 -26.08 0.0256
2025-05-20 2025-03-31 13F GILEAD SCIENCES COM 375558103 7,427 -1,100 -12.90 832 23.63 0.0433
2025-02-13 2024-12-31 13F GILEAD SCIENCES COM 375558103 8,527 4,433 108.28 674 96.21 0.0406
2024-11-13 2024-09-30 13F GILEAD SCIENCES COM 375558103 4,094 -9,049 -68.85 343 -61.93 0.0206
2024-08-02 2024-06-30 13F GILEAD SCIENCES COM 375558103 13,143 2,137 19.42 902 11.79 0.0629
2024-05-08 2024-03-31 13F GILEAD SCIENCES COM 375558103 11,006 558 5.34 806 -4.73 0.0604
2024-02-13 2023-12-31 13F GILEAD SCIENCES COM 375558103 10,448 -897 -7.91 846 -0.47 0.0743
2023-11-15 2023-09-30 13F GILEAD SCIENCES COM 375558103 11,345 3,632 47.09 850 43.10 0.0880
2023-08-15 2023-06-30 13F GILEAD SCIENCES COM 375558103 7,713 -14,674 -65.55 594 -68.01 0.0629
2023-05-15 2023-03-31 13F GILEAD SCIENCES COM 375558103 22,387 -7,267 -24.51 1,857 -27.03 0.1003
2023-02-08 2022-12-31 13F GILEAD SCIENCES COM 375558103 29,654 -6,074 -17.00 2,546 15.42 0.1538
2022-11-14 2022-09-30 13F GILEAD SCIENCES COM 375558103 35,728 -329 -0.91 2,205 -1.12 0.1490
2022-08-02 2022-06-30 13F GILEAD SCIENCES COM 375558103 36,057 4,194 13.16 2,230 17.74 0.1495
2022-04-28 2022-03-31 13F GILEAD SCIENCES COM 375558103 31,863 9,063 39.75 1,894 14.37 0.1148
2022-02-15 2021-12-31 13F GILEAD SCIENCES COM 375558103 22,800 2,445 12.01 1,656 16.46 0.1032
2021-11-15 2021-09-30 13F GILEAD SCIENCES COM 375558103 20,355 -424 -2.04 1,422 -0.63 0.0970
2021-08-09 2021-06-30 13F GILEAD SCIENCES COM 375558103 20,779 1,905 10.09 1,431 17.20 0.1030
2021-05-14 2021-03-31 13F GILEAD SCIENCES COM 375558103 18,874 -3,107 -14.13 1,221 -4.68 0.1045
2021-02-16 2020-12-31 13F GILEAD SCIENCES COM 375558103 21,981 8,598 64.25 1,281 51.42 0.1150
2020-11-13 2020-09-30 13F/A-1 GILEAD SCIENCES COM 375558103 13,383 242 1.84 846 -16.32 0.0942
2020-11-13 2020-09-30 13F GILEAD SCIENCES COM 375558103 19,360 1,447
2020-07-20 2020-06-30 13F GILEAD SCIENCES COM 375558103 13,141 -6,219 -32.12 1,011 -30.13 0.1309
2020-07-20 2020-03-31 13F GILEAD SCIENCES COM 375558103 19,360 6,322 48.49 1,447 70.84 0.2534
2020-02-18 2019-12-31 13F GILEAD SCIENCES COM 375558103 13,038 931 7.69 847 10.43 0.1075
2020-01-16 2019-09-30 13F GILEAD SCIENCES COM 375558103 12,107 -2,283 -15.87 767 -21.09 0.1241
2019-11-22 2019-06-30 13F GILEAD SCIENCES COM 375558103 14,390 6,066 72.87 972 79.67 0.1912
2019-06-11 2019-03-31 13F GILEAD SCIENCES COM 375558103 8,324 -3,577 -30.06 541 -27.28 0.1057
2019-03-06 2018-12-31 13F GILEAD SCIENCES COM 375558103 11,901 4,507 60.95 744 30.30 0.1886
2018-11-23 2018-09-30 13F GILEAD SCIENCES COM 375558103 7,394 1,007 15.77 571 26.33 0.0903
2018-08-06 2018-06-30 13F GILEAD SCIENCES COM 375558103 6,387 1,317 25.98 452 18.32 0.1263
2018-08-06 2018-03-31 13F GILEAD SCIENCES COM 375558103 5,070 -1,016 -16.69 382 -12.39 0.1113
2018-02-14 2017-12-31 13F GILEAD SCIENCES COM 375558103 6,086 163 2.75 436 -9.17 0.0955
2017-11-16 2017-09-30 13F GILEAD SCIENCES COM 375558103 5,923 5,923 480 0.1123
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.